Wednesday, July 8, 2026

Drug profile · INN

sevelamer carbonate

sevelamer carbonate (RENVELA) is a unknown. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Various (V03) V03AE02
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — sevelamer carbonate
US status
approved
Class
Various (V03)
Route
ORAL
Patents
0
Programs
1
Data quality
0.89

Quick answer

sevelamer carbonate (RENVELA) is a unknown. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN sevelamer carbonate
Brand RENVELA
Mechanism Unknown
Therapeutic class Various (V03)
Route ORAL
Formulation FOR SUSPENSION
ATC code V03AE02

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved
EMA approved

Pipeline programs

  1. Sevelamer Approved · Chinese Academy of · Degenerative Heart Valve Disease

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. ferric citrate coordination complex Various (V03)
  4. folic acid Various (V04)
  5. sugammadex sodium Various (V03)
  6. cobicistat Various (V03)

Frequently asked questions

What is sevelamer carbonate?

sevelamer carbonate (RENVELA) is a unknown. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for sevelamer carbonate?

RENVELA is a marketed brand name for sevelamer carbonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sevelamer carbonate?

sevelamer carbonate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.